Eye of Truth
Lobbyist Report for American College of Cardiology

American College of Cardiology

2400 N Street, NW Washington, DC 20037

USA

Lobbying on the following issues:

MEDICARE/MEDICAID TOBACCO HEALTH ISSUES

Medicare physician payment; new/alternative payment models; Medicare coverage, including coverage policies pertaining to transcatheter aortic valve replacement, transcatheter mitral valve repair, myocardial positron emission tomography (PET) and hospital payment; access to Medicare claims data; physician and hospital quality; electronic health record incentive program; clinical data registries; health care quality; medical imaging and prior authorization, including HR 3107; the Stark Law and the in-office ancillary services exception, including the Medicare Care Coordination Improvement Act (HR 2282); Medicare Access and CHIP Reauthorization Act implementation and oversight; Bipartisan Budget Act of 2015 and Medicare site of service policy; access to and supervision of Cardiac and Pulmonary Rehabilitation (HR 3911);graduate medical education policy including HR 1763/S 348, Resident Physician Shortage Reduction Act of 2019; end of life care; oversight and implementation of the Protecting Access to Medicare Act of 2014, including Appropriate Use Criteria; physician-owned hospital policy, Medicaid coverage and eligibility, Medicare Part B Home Infusion Services Temporary Transitional Payment Act; Affordable Care Act repeal/replace/reform efforts; Ways and Means Committee Medicare extenders policy/legislation; paclitaxel mortality signal in PAD patients; cardiac CT payment.

-

Tobacco use prevention and smoking cessation; FDA regulation of tobacco; Tobacco 21 legislation, electronic cigarettes and nicotine products; tobacco and electronic cigarette policy in House and Senate Appropriations, including S.1258, S. 1541, S. 655, S. 1832, H.R. 2339, and H.R. 2339

-

Health care quality; physician and hospital quality; health care innovation; Patient Protection and Affordable Care Act/health care reform implementation; Affordable Care Act repeal/replace/reform efforts; medical liability reform; unique device identifier policy and post-market surveillance for medical devices; clinical trial design; clinical data registries; HIPAA and registries; federal funding/appropriations for HHS, NIH, AHRQ, CDC, FDA, HRSA and the Childrens Hospital Graduate Medical Education payment program, the Prevention & Public Health Fund, medical research, and prevention; the South Asian Heart Health Awareness and Research Act (HR 3131), research and scholarly communication policy; healthy diet/lifestyle; implementation and oversight of 21st Century Cures Act; data blocking/interoperability of electronic data; health disparities; National Clinical Care Commission Act implementation; Senate price transparency workgroup; reduction/oversight of prior authorization and other administrative burdens (HR 3107); shared decision-making; medical isotope production and supply; digital health/FDA pre-certification; cardiomyopathy education and awareness; peripheral arterial disease (PAD) education and awareness; surprise medical bills/balance billing, including HR 3630, the No Surprises Act.

-

Lobbyists:

Morse, N Nicholas
MARIANI, DEBRA
VAVRICEK, JAMES
Sanders, Lucas Robert
PEREZ, CHRISTINE
Cartagena, Sarah Ali
KRISTAN, JOHNATHON
TORENTINOS, NATALIE
Rufener, Kristine R
CODY, JOSEPH
VASQUEZ, CLAUDIA

Foreign Entities:

Foreign Entity Name :
Balfour Beatty plc (parent company of Balfour Beatty Communities)
Country :
UNITED KINGDOM
Contribution :
$0
-
Foreign Entity Name :
Lendlease Group (parent company of ​Lendlease Americas)
Country :
AUSTRALIA
Contribution :
$0
-



Lobbying on the following issues:

HEALTH ISSUES MEDICARE/MEDICAID TOBACCO

Health care quality; physician and hospital quality; health care innovation; Patient Protection and Affordable Care Act/health care reform implementation; Affordable Care Act repeal/replace/reform efforts; medical liability reform; unique device identifier policy and post-market surveillance for medical devices; clinical trial design; clinical data registries; the Common Rule and registries; HIPAA and registries; federal funding/appropriations for HHS, NIH, AHRQ, CDC, FDA, HRSA and the Childrens Hospital Graduate Medical Education payment program, the Prevention & Public Health Fund, medical research, and prevention; the South Asian Heart Health Awareness and Research Act, research and scholarly communication policy; healthy diet/lifestyle; implementation and oversight of 21st Century Cures Act; data blocking/interoperability of electronic data; health disparities; National Clinical Care Commission Act implementation; Senate price transparency workgroup; reduction/oversight of prior authorization and other administrative burdens; shared decision-making; medical isotope production and supply; digital health/FDA pre-certification; cardiomyopathy education and awareness; peripheral arterial disease (PAD) education and awareness.

-

Medicare physician payment; new/alternative payment models; Medicare coverage, including coverage policies pertaining to transcatheter aortic valve replacement, transcatheter mitral valve repair, and ambulatory blood pressure monitoring; Medicare hospital payment; access to Medicare claims data; Ways & Means Committee hospital payment project; physician and hospital quality; electronic health record incentive program; clinical data registries; health care quality; medical imaging and prior authorization, including the Standardizing Electronic Prior Authorization for Safe Prescribing Act; the Stark Law and the in-office ancillary services exception, including the Medicare Care Coordination Improvement Act and the Promoting Integrity in Medicare Act; Medicare Access and CHIP Reauthorization Act implementation and oversight; Bipartisan Budget Act of 2015 and Medicare site of service policy; access to and supervision of Cardiac and Pulmonary Rehabilitation; the Advancing Care for Exceptional Kids Act of 2019 (or ACE Kids Act), a bill to allow a state, at its option, to elect to provide medical assistance for items and services furnished to eligible children with medically complex conditions enrolled in a Medicaid Children's Care Coordination (MCCC) program; Senate Finance Committee chronic care project; graduate medical education policy including HR 1763/S 348, Resident Physician Shortage Reduction Act of 2019; end of life care, Puerto Rico Oversight, Management, and Economic Stability Act (PROMESA) implementation; oversight and implementation of the Protecting Access to Medicare Act of 2014, including Appropriate Use Criteria; physician-owned hospital policy, Medicaid coverage and eligibility, Medicare Part B Home Infusion Services Temporary Transitional Payment Act; Affordable Care Act repeal/replace/reform efforts; Ways and Means Committee Medicare extenders policy/legislation.

-

Tobacco use prevention and smoking cessation; FDA regulation of tobacco; Tobacco 21 legislation, electronic cigarettes and nicotine products; tobacco and electronic cigarette policy in House and Senate Appropriations.

-

Lobbyists:

Morse, N Nicholas
GOLDSTEIN, LISA
MARIANI, DEBRA
VAVRICEK, JAMES
Sanders, Lucas Robert
PEREZ, CHRISTINE
TORENTINOS, NATALIE
Rufener, Kristine R
CODY, JOSEPH
CONKLING, BRYANT
TALLER, RHONDA
KRISTAN, JOHNATHON

Foreign Entities:

Foreign Entity Name:
NEC Corporation
Country :
JAPAN
Contribution :
$90,000



Lobbying on the following issues:

HEALTH ISSUES TOBACCO MEDICARE/MEDICAID

Health care quality; physician and hospital quality; health care innovation; Patient Protection and Affordable Care Act/health care reform implementation; Affordable Care Act repeal/replace/reform efforts; medical liability reform; unique device identifier policy and post-market surveillance for medical devices; clinical trial design; clinical data registries; the Common Rule and registries; HIPAA and registries; federal funding/appropriations for HHS, NIH, AHRQ, CDC, FDA, HRSA and the Childrens Hospital Graduate Medical Education payment program, the Prevention & Public Health Fund, medical research, and prevention; the South Asian Heart Health Awareness and Research Act, research and scholarly communication policy; healthy diet/lifestyle; implementation and oversight of 21st Century Cures Act; data blocking/interoperability of electronic data; health disparities; National Clinical Care Commission Act implementation; Senate price transparency workgroup; reduction/oversight of prior authorization and other administrative burdens; shared decision-making; medical isotope production and supply; digital health/FDA pre-certification; cardiomyopathy education and awareness; peripheral arterial disease (PAD) education and awareness; surprise medical bills/balance billing, including HR 3630, the No Surprises Act.

-

Tobacco use prevention and smoking cessation; FDA regulation of tobacco; Tobacco 21 legislation, electronic cigarettes and nicotine products; tobacco and electronic cigarette policy in House and Senate Appropriations.

-

Medicare physician payment; new/alternative payment models; Medicare coverage, including coverage policies pertaining to transcatheter aortic valve replacement, transcatheter mitral valve repair, and ambulatory blood pressure monitoring; Medicare hospital payment; access to Medicare claims data; Ways & Means Committee hospital payment project; physician and hospital quality; electronic health record incentive program; clinical data registries; health care quality; medical imaging and prior authorization, including the Standardizing Electronic Prior Authorization for Safe Prescribing Act; the Stark Law and the in-office ancillary services exception, including the Medicare Care Coordination Improvement Act and the Promoting Integrity in Medicare Act; Medicare Access and CHIP Reauthorization Act implementation and oversight; Bipartisan Budget Act of 2015 and Medicare site of service policy; access to and supervision of Cardiac and Pulmonary Rehabilitation; the Advancing Care for Exceptional Kids Act of 2019 (or ACE Kids Act), a bill to allow a state, at its option, to elect to provide medical assistance for items and services furnished to eligible children with medically complex conditions enrolled in a Medicaid Children's Care Coordination (MCCC) program; Senate Finance Committee chronic care project; graduate medical education policy including HR 1763/S 348, Resident Physician Shortage Reduction Act of 2019; end of life care, Puerto Rico Oversight, Management, and Economic Stability Act (PROMESA) implementation; oversight and implementation of the Protecting Access to Medicare Act of 2014, including Appropriate Use Criteria; physician-owned hospital policy, Medicaid coverage and eligibility, Medicare Part B Home Infusion Services Temporary Transitional Payment Act; Affordable Care Act repeal/replace/reform efforts; Ways and Means Committee Medicare extenders policy/legislation.

-

Lobbyists:

Morse, N Nicholas
GOLDSTEIN, LISA
MARIANI, DEBRA
VAVRICEK, JAMES
Sanders, Lucas Robert
PEREZ, CHRISTINE
TORENTINOS, NATALIE
Rufener, Kristine R
CODY, JOSEPH
KRISTAN, JOHNATHON
VASQUEZ, CLAUDIA

Foreign Entities:

Foreign Entity Name:
CACIF
Country :
GUATEMALA
Contribution :
$30,000



Lobbying on the following issues:

HEALTH ISSUES TOBACCO MEDICARE/MEDICAID

Health care quality; physician and hospital quality; health care innovation; Patient Protection and Affordable Care Act/health care reform implementation; Affordable Care Act repeal/replace/reform efforts; medical liability reform; unique device identifier policy and post-market surveillance for medical devices; clinical trial design; clinical data registries; HIPAA and registries; federal funding/appropriations for HHS, NIH, AHRQ, CDC, FDA, HRSA and the Childrens Hospital Graduate Medical Education payment program, the Prevention & Public Health Fund, medical research, and prevention; the South Asian Heart Health Awareness and Research Act (HR 3131), research and scholarly communication policy; healthy diet/lifestyle; implementation and oversight of 21st Century Cures Act; data blocking/interoperability of electronic data; health disparities; National Clinical Care Commission Act implementation; Senate price transparency workgroup; reduction/oversight of prior authorization and other administrative burdens (HR 3107); shared decision-making; medical isotope production and supply; digital health/FDA pre-certification; cardiomyopathy education and awareness; peripheral arterial disease (PAD) education and awareness; surprise medical bills/balance billing, including HR 3630, the No Surprises Act; COVID-19 and the coronavirus, including HR 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act, HR 6201, the Families First Coronavirus Response Act and HR 748, the Coronavirus Aid, Relief, and Economic Security Act.

-

Tobacco use prevention and smoking cessation; FDA regulation of tobacco; Tobacco 21 legislation, electronic cigarettes and nicotine products; tobacco and electronic cigarette policy in House and Senate Appropriations, including S.1258, S. 1541, S. 655, S. 1832, H.R. 2339, and H.R. 2339

-

Medicare physician payment; new/alternative payment models; Medicare coverage, including coverage policies pertaining to transcatheter aortic valve replacement, transcatheter mitral valve repair, myocardial positron emission tomography (PET) and hospital payment; access to Medicare claims data; physician and hospital quality; electronic health record incentive program; clinical data registries; health care quality; medical imaging and prior authorization, including HR 3107; the Stark Law and the in-office ancillary services exception, including the Medicare Care Coordination Improvement Act (HR 2282); Medicare Access and CHIP Reauthorization Act implementation and oversight; Bipartisan Budget Act of 2015 and Medicare site of service policy; access to and supervision of Cardiac and Pulmonary Rehabilitation (HR 3911);graduate medical education policy including HR 1763/S 348, Resident Physician Shortage Reduction Act of 2019; end of life care; oversight and implementation of the Protecting Access to Medicare Act of 2014, including Appropriate Use Criteria; physician-owned hospital policy, Medicaid coverage and eligibility, Medicare Part B Home Infusion Services Temporary Transitional Payment Act; Affordable Care Act repeal/replace/reform efforts; Ways and Means Committee Medicare extenders policy/legislation; paclitaxel mortality signal in PAD patients; cardiac CT payment; COVID-19 and the coronavirus, including HR 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act, HR 6201, the Families First Coronavirus Response Act and HR 748, the Coronavirus Aid, Relief, and Economic Security Act.

-

Lobbyists:

Morse, N Nicholas
MARIANI, DEBRA
VAVRICEK, JAMES
Sanders, Lucas Robert
PEREZ, CHRISTINE
Rufener, Kristine R
CODY, JOSEPH
Cartagena, Sarah Ali
KRISTAN, JOHNATHON
VASQUEZ, CLAUDIA
TORENTINOS, NATALIE

Foreign Entities:

Foreign Entity Name:
Horizon Pharma PLC
Country :
IRELAND
Contribution :
$0



Lobbying on the following issues:

HEALTH ISSUES TOBACCO MEDICARE/MEDICAID

Health care quality; physician and hospital quality; health care innovation; Patient Protection and Affordable Care Act/health care reform implementation; Affordable Care Act repeal/replace/reform efforts; medical liability reform, including HR 1215, the Protecting Access to Care Act; unique device identifier policy and post-market surveillance for medical devices; clinical trial design; clinical data registries; the Common Rule and registries; HIPAA and registries; federal funding/appropriations for HHS, NIH, AHRQ, CDC, FDA, HRSA and the Childrens Hospital Graduate Medical Education payment program, including H.R. 5385, the Prevention & Public Health Fund, medical research, and prevention; HR 3592, the South Asian Heart Health Awareness and Research Act of 2017; research and scholarly communication policy, including S 1701/HR 3427, the Fair Access to Science and Technology Research Act of 2017; healthy diet/lifestyle; implementation and oversight of 21st Century Cures Act; data blocking/interoperability of electronic data; health disparities; S 477/HR 1222, the Congenital Heart Futures Reauthorization Act of 2017; National Clinical Care Commission Act implementation; Senate price transparency workgroup; reduction/oversight of prior authorization and other administrative burdens; shared decision-making; medical isotope production and supply; digital health/FDA pre-certification; cardiomyopathy education and awareness; peripheral arterial disease (PAD) education and awareness.

-

Tobacco use prevention and smoking cessation; FDA regulation of tobacco; HR 1136, FDA Deeming Authority Clarification Act of 2017 and S 294/HR 564, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act; electronic cigarettes and nicotine products; tobacco and electronic cigarette policy in House and Senate Appropriations.

-

Medicare physician payment; new/alternative payment models; Medicare coverage, including coverage policies pertaining to transcatheter aortic valve replacement, transcathether mitral valve repair, and ambulatory blood pressure monitoring; Medicare hospital payment; access to Medicare claims data; Ways & Means Committee hospital payment project; physician and hospital quality; electronic health record incentive program; clinical data registries; health care quality; medical imaging and prior authorization, including HR 4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018; the Stark Law and the in-office ancillary services exception, including HR 4206/S 2051, the Medicare Care Coordination Improvement Act; Promoting Integrity in Medicare Act, HR 2066; Medicare Access and CHIP Reauthorization Act implementation and oversight; Bipartisan Budget Act of 2015 and Medicare site of service policy; HR 1155/S 1361, a bill to amend title XVIII of the Social Security Act to allow physician assistants, nurse practitioners, and clinical nurse specialists to supervise cardiac, intensive cardiac, and pulmonary rehabilitation programs; S 46, the Strengthening Medicare Intensive Cardiac Rehabilitation Programs Act of 2017; HR 3325/S 428, The Advancing Care for Exceptional Kids Act of 2017 (or ACE Kids Act), a bill to allow a state, at its option, to elect to provide medical assistance for items and services furnished to eligible children with medically complex conditions enrolled in a Medicaid Children's Care Coordination (MCCC) program; Senate Finance Committee chronic care project; graduate medical education policy including HR 2267/S 1301, Resident Physician Shortage Reduction Act of 2017; end of life care, including HR 2797/S 1334, the Patient Choice and Quality Care Act of 2017; Puerto Rico Oversight, Management, and Economic Stability Act (PROMESA) implementation; oversight and implementation of the Protecting Access to Medicare Act of 2014, including Appropriate Use Criteria; physician-owned hospital policy, including HR 1156/S 1133, the Patient Access to High Quality Care Act of 2017; Medicaid coverage and eligibility, including HR 829, Prioritizing the Most Vulnerable Over Lottery Winners Act of 2017, HR 181, Close Annuity Loopholes in Medicaid Act, and HR 705, Verify Eligibility Coverage Act; HR 3163, Medicare Part B Home Infusion Services Temporary Transitional Payment Act; Affordable Care Act repeal/replace/reform efforts; HR 3767 and S 989, the Ensuring Childrens Access to Specialty Care Act of 2017; HR 3635, the Local Coverage Determination Clarification Act of 2017; Ways and Means Committee Medicare extenders policy/legislation.

-

Lobbyists:

Morse, N Nicholas
GOLDSTEIN, LISA
MARIANI, DEBRA
VAVRICEK, JAMES
Sanders, Lucas Robert
PEREZ, CHRISTINE
TORENTINOS, NATALIE
Rufener, Kristine R
CODY, JOSEPH
CONKLING, BRYANT
TALLER, RHONDA

Foreign Entities:

Foreign Entity Name:
Fresenius Medical Care AG and Co. KGaA is the sole indirect owner of Fresenius Medical Care Holdings, Inc. (dba Fresenius Medical Care North America)
Country :
GERMANY
Contribution :
$0



Lobbying on the following issues:

TOBACCO HEALTH ISSUES MEDICARE/MEDICAID

Tobacco use prevention and smoking cessation; FDA regulation of tobacco; Tobacco 21 legislation, electronic cigarettes and nicotine products; tobacco and electronic cigarette policy in House and Senate Appropriations, including S.1258, S. 1541, S. 655, S. 1832, H.R. 2339, and H.R. 2339

-

Health care quality; physician and hospital quality; health care innovation; Patient Protection and Affordable Care Act/health care reform implementation; Affordable Care Act repeal/replace/reform efforts; medical liability reform; unique device identifier policy and post-market surveillance for medical devices; clinical trial design; clinical data registries; HIPAA and registries; federal funding/appropriations for HHS, NIH, AHRQ, CDC, FDA, HRSA and the Childrens Hospital Graduate Medical Education payment program, the Prevention & Public Health Fund, medical research, and prevention; the South Asian Heart Health Awareness and Research Act (HR 3131), research and scholarly communication policy; healthy diet/lifestyle; implementation and oversight of 21st Century Cures Act; data blocking/interoperability of electronic data; health disparities; National Clinical Care Commission Act implementation; Senate price transparency workgroup; reduction/oversight of prior authorization and other administrative burdens (HR 3107); shared decision-making; medical isotope production and supply; digital health/FDA pre-certification; cardiomyopathy education and awareness; peripheral arterial disease (PAD) education and awareness; surprise medical bills/balance billing, including HR 3630, the No Surprises Act.

-

Medicare physician payment; new/alternative payment models; Medicare coverage, including coverage policies pertaining to transcatheter aortic valve replacement, transcatheter mitral valve repair, myocardial positron emission tomography (PET) and hospital payment; access to Medicare claims data; physician and hospital quality; electronic health record incentive program; clinical data registries; health care quality; medical imaging and prior authorization, including HR 3107; the Stark Law and the in-office ancillary services exception, including the Medicare Care Coordination Improvement Act (HR 2282); Medicare Access and CHIP Reauthorization Act implementation and oversight; Bipartisan Budget Act of 2015 and Medicare site of service policy; access to and supervision of Cardiac and Pulmonary Rehabilitation (HR 3911);graduate medical education policy including HR 1763/S 348, Resident Physician Shortage Reduction Act of 2019; end of life care; oversight and implementation of the Protecting Access to Medicare Act of 2014, including Appropriate Use Criteria; physician-owned hospital policy, Medicaid coverage and eligibility, Medicare Part B Home Infusion Services Temporary Transitional Payment Act; Affordable Care Act repeal/replace/reform efforts; Ways and Means Committee Medicare extenders policy/legislation; paclitaxel mortality signal in PAD patients; cardiac CT payment.

-

Lobbyists:

Morse, N Nicholas
MARIANI, DEBRA
VAVRICEK, JAMES
Sanders, Lucas Robert
PEREZ, CHRISTINE
Rufener, Kristine R
KRISTAN, JOHNATHON
VASQUEZ, CLAUDIA
TORENTINOS, NATALIE
CODY, JOSEPH

Foreign Entities:

Foreign Entity Name:
Barrick Gold Corporation
Country :
CANADA
Contribution :
$0



Money Spent:

Amount Client Government Entities

$890,000

Jan 21, 2020

FOURTH QUARTER REPORT

AMERICAN COLLEGE OF CARDIOLOGY

HOUSE OF REPRESENTATIVES
Agency for Healthcare Research & Quality (AHRQ)
Food & Drug Administration (FDA)
Medicare Payment Advisory Commission (MedPAC)
SENATE
White House Office
Health & Human Services, Dept of (HHS)
Natl Institutes of Health (NIH)
Centers For Disease Control & Prevention (CDC)
Office of Management & Budget (OMB)
Centers For Medicare and Medicaid Services (CMS)

$530,000

Apr 22, 2019

FIRST QUARTER REPORT

AMERICAN COLLEGE OF CARDIOLOGY

HOUSE OF REPRESENTATIVES
Agency for Healthcare Research & Quality (AHRQ)
Food & Drug Administration (FDA)
Medicare Payment Advisory Commission (MedPAC)
SENATE
White House Office
Health & Human Services, Dept of (HHS)
Natl Institutes of Health (NIH)
Centers For Disease Control & Prevention (CDC)
Office of Management & Budget (OMB)
Centers For Medicare and Medicaid Services (CMS)

$520,000

Jul 19, 2019

SECOND QUARTER REPORT

AMERICAN COLLEGE OF CARDIOLOGY

HOUSE OF REPRESENTATIVES
Agency for Healthcare Research & Quality (AHRQ)
Food & Drug Administration (FDA)
Medicare Payment Advisory Commission (MedPAC)
SENATE
White House Office
Health & Human Services, Dept of (HHS)
Natl Institutes of Health (NIH)
Centers For Disease Control & Prevention (CDC)
Office of Management & Budget (OMB)
Centers For Medicare and Medicaid Services (CMS)

$500,000

Apr 20, 2020

FIRST QUARTER REPORT

AMERICAN COLLEGE OF CARDIOLOGY

HOUSE OF REPRESENTATIVES
Agency for Healthcare Research & Quality (AHRQ)
Food & Drug Administration (FDA)
Medicare Payment Advisory Commission (MedPAC)
SENATE
White House Office
Health & Human Services, Dept of (HHS)
Natl Institutes of Health (NIH)
Centers For Disease Control & Prevention (CDC)
Office of Management & Budget (OMB)
Centers For Medicare and Medicaid Services (CMS)

$480,000

Jan 22, 2019

FOURTH QUARTER REPORT

AMERICAN COLLEGE OF CARDIOLOGY

HOUSE OF REPRESENTATIVES
Agency for Healthcare Research & Quality (AHRQ)
Food & Drug Administration (FDA)
Medicare Payment Advisory Commission (MedPAC)
SENATE
White House Office
Health & Human Services, Dept of (HHS)
Natl Institutes of Health (NIH)
Centers For Disease Control & Prevention (CDC)
Office of Management & Budget (OMB)
Centers For Medicare and Medicaid Services (CMS)

$410,000

Oct 21, 2019

THIRD QUARTER REPORT

AMERICAN COLLEGE OF CARDIOLOGY

HOUSE OF REPRESENTATIVES
Agency for Healthcare Research & Quality (AHRQ)
Food & Drug Administration (FDA)
Medicare Payment Advisory Commission (MedPAC)
SENATE
White House Office
Health & Human Services, Dept of (HHS)
Natl Institutes of Health (NIH)
Centers For Disease Control & Prevention (CDC)
Office of Management & Budget (OMB)
Centers For Medicare and Medicaid Services (CMS)